Reply to the Letter by Kaya Entitled 'Fluctuation Speed as a New Criterion to Evaluate the Efficiency of Intravitreal Anti-VEGF Drugs'.
Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland.
Martin S
MS
Zinkernagel
Sebastian
S
Wolf
Andreas
A
Ebneter
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D001082:Aqueous Humor / Q000187:drug effects / Q000502:physiology*; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D058449:Intravitreal Injections; D012163:Retinal Detachment / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab